A Research Agenda for Malaria Eradication: Vaccines

The Malaria Eradication Research Agenda (malERA) Consultative Group on Vaccines present a research and development agenda to provide the tools to create vaccines that may be used during malaria eradication.

[1]  A. Holder,et al.  Function of Region I and II Adhesive Motifs ofPlasmodium falciparum Circumsporozoite Protein in Sporozoite Motility and Infectivity* , 2002, The Journal of Biological Chemistry.

[2]  Kim-Sung Lee,et al.  Plasmodium knowlesi from archival blood films: Further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo , 2009, International journal for parasitology.

[3]  M. Khatri,et al.  Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. , 2009, The American journal of tropical medicine and hygiene.

[4]  Yongyuth Yuthavong,et al.  A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.

[5]  R. Adegbola,et al.  Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study , 2005, The Lancet.

[6]  Anil K Ghosh,et al.  Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen , 2007, Proceedings of the National Academy of Sciences.

[7]  R. Snow,et al.  Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya , 2008, The Lancet.

[8]  Nicolas Maire,et al.  What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines , 2008, PloS one.

[9]  C. Plowe,et al.  Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’ , 2009, Parasite immunology.

[10]  Nicholas J White,et al.  Vivax malaria: neglected and not benign. , 2007, The American journal of tropical medicine and hygiene.

[11]  E. Angov,et al.  A Potent Malaria Transmission Blocking Vaccine Based on Codon Harmonized Full Length Pfs48/45 Expressed in Escherichia coli , 2009, PloS one.

[12]  Q. Bassat,et al.  Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial , 2005, The Lancet.

[13]  Petra Schneider,et al.  Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. , 2006, The Journal of infectious diseases.

[14]  M. Levine,et al.  The Role of Research in Viral Disease Eradication and Elimination Programs: Lessons for Malaria Eradication , 2011, PLoS medicine.

[15]  M. Dixon,et al.  Sex in Plasmodium: a sign of commitment. , 2008, Trends in parasitology.

[16]  S. Hoffman,et al.  Antibodies against the Plasmodium falciparum Receptor Binding Domain of EBA-175 Block Invasion Pathways That Do Not Involve Sialic Acids , 2000, Infection and Immunity.

[17]  Priyabrata Pattnaik,et al.  Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. , 2002, Molecular and biochemical parasitology.

[18]  David Schellenberg,et al.  A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics , 2011, PLoS medicine.

[19]  D. Henderson.  Principles and lessons from the smallpox eradication programme. , 1987, Bulletin of the World Health Organization.

[20]  J. John.  Role of injectable and oral polio vaccines in polio eradication , 2009, Expert review of vaccines.

[21]  M. Fay,et al.  Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.

[22]  Zbynek Bozdech,et al.  Antibodies Targeting the PfRH1 Binding Domain Inhibit Invasion of Plasmodium falciparum Merozoites , 2008, PLoS pathogens.

[23]  Surveillance..  A Research Agenda for Malaria Eradication: Monitoring, Evaluation, and Surveillance , 2011, PLoS medicine.

[24]  J. Acharya,et al.  Thrombocytopenia in Plasmodium falciparum, Plasmodium vivax and mixed infection malaria: A study from Bikaner (Northwestern India) , 2010, Platelets.

[25]  D. Conway,et al.  Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis , 2008, The Lancet.

[26]  Frank H. Collins,et al.  A Research Agenda for Malaria Eradication: Vector Control , 2011, PLoS medicine.

[27]  J Mouchet,et al.  DDT house spraying and re-emerging malaria , 2000, The Lancet.

[28]  A Research Agenda for Malaria Eradication: Cross-Cutting Issues for Eradication , 2011, PLoS medicine.

[29]  Sumana Chakravarty,et al.  Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria , 2010, Human vaccines.

[30]  C. Chitnis,et al.  Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. , 1994, Science.

[31]  S. D. de Vlas,et al.  Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data , 2005, Parasitology.

[32]  K. Mendis,et al.  The neglected burden of Plasmodium vivax malaria. , 2001, The American journal of tropical medicine and hygiene.

[33]  V. Nussenzweig,et al.  The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of plasmodium falciparum sporozoites , 1992, Cell.

[34]  C. Chitnis,et al.  Plasmodium vivax Invasion of Human Erythrocytes Inhibited by Antibodies Directed against the Duffy Binding Protein , 2007, PLoS medicine.

[35]  Priyabrata Pattnaik,et al.  Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. , 2007, Vaccine.

[36]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[37]  A. Crisanti,et al.  The A‐domain and the thrombospondin‐related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands , 1999, The EMBO journal.

[38]  R. Carter.  Transmission blocking malaria vaccines. , 2001, Vaccine.

[39]  M. Mota,et al.  Migration through host cells activates Plasmodium sporozoites for infection , 2003, Nature Medicine.

[40]  A. Holder,et al.  Effective induction of high-titer antibodies by viral vector vaccines , 2008, Nature Medicine.

[41]  Thomas Smith,et al.  A Research Agenda for Malaria Eradication: Modeling , 2011, PLoS medicine.

[42]  Manuel Llinás,et al.  A Research Agenda for Malaria Eradication: Basic Science and Enabling Technologies , 2011, PLoS medicine.

[43]  R. Price,et al.  New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance , 2009, Current opinion in infectious diseases.

[44]  W. Moss,et al.  Global measles elimination , 2006, Nature Reviews Microbiology.

[45]  H. Stunnenberg,et al.  Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice , 2008, Proceedings of the National Academy of Sciences.

[46]  A. Das,et al.  Plasmodium vivax Malaria , 2005, Emerging infectious diseases.

[47]  D. Conway,et al.  Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  J. Sattabongkot,et al.  Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. , 2005, Vaccine.

[49]  Andrea Crisanti,et al.  TRAP Is Necessary for Gliding Motility and Infectivity of Plasmodium Sporozoites , 1997, Cell.